Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 11, 2013, Pages 1835-1843

  Kang, Byung Woog ^a   Lee, Dakeun ^a   Chung, Ho Young ^a   Han, Jae Ho ^b   Kim, Young Bae ^b  

^a Kyungpook National University Hospital   (South Korea)

^b Ajou University School of Medicine   (South Korea)

Author keywords

C erbB2; C Met; CD151; Gastric cancer; Prognosis

Indexed keywords

CD151 ANTIGEN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; SCATTER FACTOR RECEPTOR; TETRASPANIN; ANTINEOPLASTIC AGENT; CD151 PROTEIN, HUMAN; DRUG COMBINATION; OTERACIL; PROTEIN TYROSINE KINASE; RON PROTEIN; S 1 (COMBINATION); TEGAFUR; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GASTRECTOMY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL GASTRECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURVIVAL RATE; TUMOR INVASION; TUMOR VOLUME; VERY ELDERLY; YOUNG ADULT; ABDOMINAL SURGERY; ADENOCARCINOMA; BIOSYNTHESIS; COHORT ANALYSIS; DRUG COMBINATION; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; PILOT STUDY; PROGNOSIS; STOMACH NEOPLASMS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD151; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COHORT STUDIES; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DRUG COMBINATIONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODE EXCISION; MALE; MIDDLE AGED; OXONIC ACID; PILOT PROJECTS; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TEGAFUR; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84892648238     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1503-4     Document Type: Article

References (33)

1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697
2. Blum MA, Takashi T, Suzuki A, Ajani JA (2013) Management of localized gastric cancer. J Surg Oncol 107:265-270
3. Deng X, Li Q, Hoff J, Novak M, Yang H, Jin H, Erfani SF, Sharma C, Zhou P, Rabinovitz I, Sonnenberg A, Yi Y, Zhou P, Stipp CS, Kaetzel DM, Hemler ME, Yang XH (2012) Integrin-associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis. Neoplasia 14:678-689
4. Franco M, Muratori C, Corso S, Tenaglia E, Bertotti A, Capparuccia L, Trusolino L, Comoglio PM, Tamagnone L (2010) The tetraspanin CD151 is required for Met-dependent signaling and tumor cell growth. J Biol Chem 285:38756-38764
5. Guggenheim DE, Shah MA (2013) Gastric cancer epidemiology and risk factors. J Surg Oncol 107:230-236
6. Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park JO, Kang WK, Choi MG, Sohn TS, Bae JM,KimS, KimM, KimS, Park CK, IgnatiusOu SH, Kim KM (2013) MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol [Epub ahead of print]
7. Hemler ME (2008) Targeting of tetraspanin proteins-potential benefits and strategies. Nat Rev Drug Discov 7:747-758
8. Huang XY, Ke AW, Shi GM, Ding ZB, Devbhandari RP, Gu FM, Li QL, Dai Z, Zhou J, Fan J (2010) Overexpression of CD151 as an adverse marker for intrahepatic cholangiocarcinoma patients. Cancer 116:5440-5451
9. Jain S, Filipe MI, Gullick WJ, Linehan J, Morris RW (1991) c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: an immunohistochemical study on archival material. Int J Cancer 48:668-671
10. Jorgensen JT, Hersom M (2012) HER2 as a prognostic marker in gastric cancer-a systematic analysis of data from the literature. J Cancer 3:137-144
11. Kang BW, Kim JG, Chae YS, Lee YJ, Lee SJ, Moon JH, Sohn SK, Jung MK, Jeon SW, Jang YJ, Seo J, Lee YH, Kwon O, Chung HY, Yu W (2012) Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer. Invest New Drugs 30:1671-1675
12. Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, Xu Y, Song ZJ, Wang ZJ, Wu JC, Bai DS, Li JC, Liu KD, Fan J (2009) Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 49:491-503
13. Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, Jang SJ, Park YS (2011) Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 18:2833-2840
14. Klosek SK, Nakashiro K, Hara S, Shintani S, Hasegawa H, Hamakawa H (2005) CD151 forms a functional complex with c-Met in human salivary gland cancer cells. Biochem Biophys Res Commun 336:408-416
15. Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK (2012) HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 20:13-24
16. Kwon MJ, Park S, Choi JY, Oh E, Kim YJ, Park YH, Cho EY, Kwon MJ, Nam SJ, Im YH, Shin YK, Choi YL (2012) Clinical significance of CD151 overexpression in subtypes of invasive breast cancer. Br J Cancer 106:923-930
17. Lee KE, Lee HJ, Kim YH, Yu HJ, Yang HK, Kim WH, Lee KU, Choe KJ, Kim JP (2003) Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol 33:173-179
18. Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Jang HL, Kim JY, Kim KM, Kang WK, Park JO (2011) Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 25:1517-1524
19. Lee D, Suh YL, Park TI, Do IG, Seol HJ, Nam DH, Kim ST (2012a) Prognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas. J Surg Oncol 107(6):646-652
20. Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, Lee BL, Bang YJ, Kim WH (2012b) MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 107:325-333
21. Romanska HM, Berditchevski F (2011) Tetraspanins in human epithelial malignancies. J Pathol 223:4-14
22. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncol 14:320-368
23. Sadej R, Romanska H, Kavanagh D, Baldwin G, Takahashi T, Kalia N, Berditchevski F (2010) Tetraspanin CD151 regulates transforming growth factor beta signaling: implication in tumor metastasis. Cancer Res 70:6059-6070
24. Suzuki S, Miyazaki T, Tanaka N, Sakai M, Sano A, Inose T, Sohda M, Nakajima M, Kato H, Kuwano H (2011) Prognostic significance of CD151 expression in esophageal squamous cell carcinoma with aggressive cell proliferation and invasiveness. Ann Surg Oncol 18:888-893
25. Testa JE, Brooks PC, Lin JM, Quigley JP (1999) Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Cancer Res 59:3812-3820
26. Viudez-Berral A, Miranda-Murua C, Arias-de-la-Vega F, Hernandez-Garcia I, Artajona-Rosino A, Diaz-de-Liano A, Vera-Garcia R (2012) Current management of gastric cancer. Rev Esp Enferm Dig 104:134-141
27. Voss MA, Gordon N, Maloney S, Ganesan R, Ludeman L, McCarthy K, Gornall R, Schaller G, Wei W, Berditchevski F, Sundar S (2011) Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer. Br J Cancer 104:1611-1618
28. Yan SY, Hu Y, Fan JG, Tao GQ, Lu YM, Cai X, Yu BH, Du YQ (2011) Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol 17:1501-1506
29. Yang XH, Richardson AL, Torres-Arzayus MI, Zhou P, Sharma C, Kazarov AR, Andzelm MM, Strominger JL, Brown M, Hemler ME (2008) CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization. Cancer Res 68:3204-3213
30. Yang XH, Flores LM, Li Q, Zhou P, Xu F, Krop IE, Hemler ME (2010) Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res 70:2256-2263
31. Yang YM, Zhang ZW, Liu QM, Sun YF, Yu JR, Xu WX (2013) Overexpression of CD151 predicts prognosis in patients with resected gastric cancer. PLoS ONE 8:e58990
32. Yoo SH, Lee K, Chae JY, Moon KC (2011) CD151 expression can predict cancer progression in clear cell renal cell carcinoma. Histopathology 58:191-197
33. Zoller M (2009) Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer 9:40-55